Skip to content
Clinical Trials – home
Not yet recruiting

Efficacy and Safety of Maridebart Cafraglutide (AMG 133) versus Placebo in Adults with Type 2 Diabetes Inadequately Controlled on Basal Insulin

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

People with Type 2 Diabetes whose blood sugar is not well controlled despite using basal insulin may receive a new injectable medicine called maridebart cafraglutide (code name AMG 133) or a harmless substance known as placebo during the study.

The aim of the research is to find out whether the new medicine can lower blood sugar better than the placebo, as measured by a blood test called HbA1c. Additional goals include looking at changes in body weight and whether participants can reach target blood‑sugar levels.

People are assigned to one of the two groups by chance and neither the participants nor the study staff know which treatment is given. The assigned injection is given under the skin at regular visits, and participants attend scheduled appointments for safety checks, blood tests, and other routine assessments over the study period.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit and Randomization

    You attend a clinic for the first study visit after joining the trial. During this visit, basic health information, blood tests, and weight are recorded.

    Based on these measurements, you are randomly assigned to receive either maridebart cafraglutide or a matching placebo. The assignment is double‑blind, meaning you will not know which one you receive.

  2. Step 2

    First Injection

    You receive a single subcutaneous injection (an injection under the skin) of the assigned study medication.

    The injection contains the dose specified in the study protocol, which is 0 mg of maridebart cafraglutide or an equivalent volume of placebo.

  3. Step 3

    Ongoing Injections

    You continue to receive additional subcutaneous injections of the same study medication at regular intervals as instructed by the study team.

    These injections are administered throughout the entire study period, ending at the final visit.

  4. Step 4

    Regular Follow‑Up Visits

    At scheduled clinic visits, you undergo blood tests, including the HbA1c test, which measures average blood‑sugar levels over the past few months, and body‑weight measurements.

    The results help determine how well the medication is working and whether any safety concerns arise.

  5. Step 5

    Final Assessment

    At the end of the trial, you attend a final clinic visit where the same set of measurements (blood tests, weight, and any other required assessments) are performed.

    After the final assessment, you will be transitioned back to standard medical care.

Who can join the trial?

8 criteria

  • Signed informed consent before any study procedures are started.
  • Be at least 18 years old (or the legal adult age in your country) when you sign the consent.
  • Have a documented diagnosis of Type 2 Diabetes according to World Health Organization criteria.
  • Blood test showing an HbA1c level of 7.0% or higher but not more than 10.5% (HbA1c is a measure of average blood sugar over the past 2‑3 months).
  • Be on a stable dose of daily basal insulin (long‑acting insulin such as glargine or degludec) at a dose greater than 0.25 units per kilogram of body weight per day or more than 20 units per day, with or without the pill metformin (at least 1500 mg per day or the highest dose you can tolerate) and possibly an SGLT‑2 inhibitor (another type of diabetes medication), for at least 90 days before randomization. “Stable” means the insulin dose stayed within ± 20% of the starting dose during those 90 days.
  • Have a Body Mass Index (BMI) of 23 kg/m² or higher at screening (BMI is a calculation using your height and weight to estimate body fat).
  • If you could become pregnant, you must use the study‑required contraception during the treatment period and for a set time after the last dose.
  • Be able and willing to follow the study requirements, including doing self‑monitoring of blood glucose (SMBG) at home and completing study diaries.

Who cannot join the trial?

33 criteria

  • Having type 1 diabetes (a different kind of diabetes), a history of ketoacidosis (dangerously high blood acids) or a hyperosmolar coma, or any other type of diabetes besides type 2 or past gestational diabetes.
  • Having an active autoimmune disease such as lupus or rheumatoid arthritis that has required, or is likely to require, strong steroids called systemic glucocorticoids within the past 90 days.
  • Using any blood‑sugar‑lowering medication other than basal insulin (long‑acting insulin), insulin glargine (U‑100 or U‑300), insulin degludec, metformin, or SGLT‑2 inhibitors within 90 days before joining the study (short‑term non‑basal insulin for an acute illness is allowed).
  • Having a history of chronic pancreatitis (long‑lasting inflammation of the pancreas).
  • Using weight‑loss drugs or supplements (for example, GLP‑1 receptor agonists, phentermine, naltrexone/bupropion, orlistat, or similar medicines) within 90 days before joining.
  • Taking systemic steroids for more than 14 days within the 90 days before joining (topical or inhaled steroids are not counted).
  • Starting or changing the dose of medicines that cause significant weight gain (such as certain antidepressants, antipsychotics, or mood stabilizers) within 90 days before joining or planning to change them during the trial.
  • Currently receiving a study drug, or having finished another study drug less than 90 days (or less than five drug half‑lives) ago.
  • Having a thyroid‑stimulating hormone (TSH) level lower than 0.4 mIU/L, or higher than 6.0 mIU/L with low free thyroxine, at the screening visit (stable hypothyroidism treatment is allowed).
  • Having kidney function measured as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², or being on dialysis.
  • Having active liver disease (such as hepatitis), an ALT level more than three times the normal limit, or a total bilirubin level more than 1.2 times normal (Gilbert syndrome is not excluded).
  • Having experienced a severe (Level 3) low‑blood‑sugar episode that required help from another person within the past 180 days.
  • Having had an episode of acute pancreatitis within the past 180 days.
  • Having a heart attack, major heart surgery, stroke, unstable angina, heart‑failure hospitalization, or a transient ischemic attack within the past 60 days.
  • Having New York Heart Association Class IV heart failure (advanced heart failure).
  • Having received an organ transplant (except a corneal transplant) or being on an organ‑transplant waiting list.
  • Having a serious stomach‑emptying problem such as gastroparesis or gastric outlet obstruction.
  • Having a history of ischemic optic neuropathy (eye damage caused by poor blood flow).
  • Receiving or planning treatment for diabetic eye disease (like laser therapy or eye injections) or having advanced diabetic retinopathy or maculopathy.
  • Having a blood disorder (such as hemolytic anemia or sickle‑cell disease) that could affect the accuracy of the HbA1c test.
  • Being judged by the doctor as unlikely to complete all required study visits and procedures.
  • Being currently pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
  • Having a history of hypoglycemia unawareness (not feeling low‑blood‑sugar symptoms) or poor recognition of low‑blood‑sugar signs.
  • Being unwilling to avoid donating blood or plasma while in the study.
  • Planning any medical or surgical procedure that requires deep sedation or general anesthesia and could interfere with study participation.
  • Being a study‑site staff member or an immediate family member (spouse, parent, child, or sibling) of a staff member.
  • Having any other serious illness or condition that the investigator believes would make participation unsafe or could interfere with the study results.
  • Having lost or gained more than 5 % of body weight in the 90 days before screening, and being unwilling to avoid an intensive diet or exercise program aimed at rapid weight loss during the trial.
  • Planning or having recent (within 1 year) obesity surgery or device treatment, except for certain old procedures such as liposuction performed more than a year ago.
  • Having a known allergy or sensitivity to the study drug or any of its ingredients.
  • Having had cancer (malignancy) within the past 5 years, except for treated non‑melanoma skin cancer, ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix.
  • Having multiple endocrine neoplasia type 2 (MEN‑2) or a first‑degree relative with medullary thyroid carcinoma.
  • Having a condition such as drug or alcohol abuse or a psychiatric disorder that, in the investigator’s opinion, would prevent you from following the study protocol.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AMG 133 is an experimental injection that contains the active ingredient maridebart cafraglutide. In this study, participants receive the medicine under the skin (subcutaneous use) as a liquid solution. The drug is being tested to see if it can help lower blood sugar levels in people with type 2 diabetes who are already using basal insulin.

What is already known about the treatment

  • Maridebart Cafraglutide

    This medication is given as a clear solution that is injected under the skin. It is still being studied in late‑stage clinical trials and is not yet approved for regular medical use. It is aimed at people with type 2 diabetes whose blood sugar is not well controlled with basal insulin. The drug works by copying a natural hormone that tells the pancreas to release more insulin after meals and helps lower appetite, and it belongs to the class of GLP‑1 receptor agonists.

  • Placebo

    The placebo is a harmless liquid that is also injected under the skin, but it contains no active drug. It is used only in research studies to compare the effects of the real medication. It has no therapeutic purpose or known action in the body. The placebo serves as a control to help scientists see whether the test drug truly works.

Investigated diseases

Type 2 diabetes mellitus inadequately controlled with basal insulin - Type 2 diabetes mellitus is a chronic condition in which the body does not use insulin effectively, leading to high blood sugar. Over time, the pancreas may produce less insulin, and blood glucose remains elevated. When basal insulin therapy does not keep blood sugar at target levels, the disease is considered inadequately controlled. Persistent high glucose can cause the condition to worsen, with increasing difficulty maintaining normal levels. The disease often progresses gradually, with symptoms such as increased thirst, urination, and fatigue becoming more noticeable.
Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-523773-42-00Protocol code20230232Estimated enrolment456 patientsSponsorAmgen Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.